Abstract
Caspofungin, an echinocandin, is approved for use in invasive candidiasis. Few cases of break-through candidal infections during caspofungin therapy have been reported and none have involved Candida parapsilosis. Here, we report a patient who developed multiple post-operative complications after pancreaticoduodenectomy for a pancreatic mass, including fungemia due to C. parapsilosis, while on caspofungin for treatment of Candida glabrata peritonitis. The fungemia resolved after a central venous catheter was removed and therapy was switched from caspofungin to amphotericin B lipid complex. Studies of C. parapsilosis susceptibility and the pharmacodynamics and drug interactions of caspofungin that may contribute to breakthrough fungemia are discussed.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cheung, C., Guo, Y., Gialanella, P. et al. Development of Candidemia on Caspofungin Therapy: a Case Report. Infection 34, 345–348 (2006). https://doi.org/10.1007/s15010-006-5613-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s15010-006-5613-7